Coordinatore | UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
Nazionalità Coordinatore | Switzerland [CH] |
Sito del progetto | http://www.do-health.eu |
Totale costo | 13˙067˙695 € |
EC contributo | 5˙999˙548 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2011-two-stage |
Funding Scheme | CP-FP |
Anno di inizio | 2012 |
Periodo (anno-mese-giorno) | 2012-01-01 - 2017-06-30 |
# | ||||
---|---|---|---|---|
1 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | coordinator | 1˙479˙647.80 |
2 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 798˙125.06 |
3 |
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
Organization address
address: "Rue Viguerie, Hotel-Dieu Saint Jacques 2" contact info |
FR (TOULOUSE) | participant | 704˙093.00 |
4 |
UNIVERSIDADE DE COIMBRA
Organization address
address: PACO DAS ESCOLAS contact info |
PT (COIMBRA) | participant | 677˙031.00 |
5 |
FERRARI DATA SOLUTIONS GMBH
Organization address
address: FELDGUETLIWEG 152 152 contact info |
CH (MEILEN) | participant | 452˙568.00 |
6 |
UNIVERSITAETSSPITAL BASEL
Organization address
address: HEBELSTRASSE 32 contact info |
CH (BASEL) | participant | 451˙881.00 |
7 |
UNIVERSITE DE GENEVE
Organization address
address: Rue du General Dufour 24 contact info |
CH (GENEVE) | participant | 368˙950.00 |
8 |
MEDIZINISCHE UNIVERSITAET INNSBRUCK
Organization address
address: Christoph-Probst Platz 1 contact info |
AT (INNSBRUCK) | participant | 358˙450.00 |
9 |
ACIES Consulting Group SAS
Organization address
city: LYON contact info |
FR (LYON) | participant | 180˙000.00 |
10 |
GUT BENNO PHILIPP ALOIS
Organization address
address: RIGIWEG 9 contact info |
CH (HORGEN) | participant | 129˙000.00 |
11 |
PHARMALYS LTD
Organization address
address: WARWICK ROAD WARWICK HOUSE contact info |
UK (BOREHAMWOOD) | participant | 115˙000.00 |
12 |
TECHNISCHE UNIVERSITAET DRESDEN
Organization address
address: HELMHOLTZSTRASSE 10 contact info |
DE (DRESDEN) | participant | 90˙000.00 |
13 |
MAX RUBNER INSTITUT BUNDESFORSCHUNGSINSTITUT FUR ERNAHRUNG UND LEBENSMITTEL
Organization address
address: HAID UND NEU STRASSE 9 contact info |
DE (KARLSRUHE) | participant | 67˙500.00 |
14 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | participant | 44˙318.00 |
15 |
THE UNIVERSITY OF SHEFFIELD
Organization address
address: FIRTH COURT WESTERN BANK contact info |
UK (SHEFFIELD) | participant | 37˙568.00 |
16 |
INTERNATIONAL OSTEOPOROSIS FOUNDATION
Organization address
address: RUE JUSTE OLIVIER 9 contact info |
CH (NYON) | participant | 30˙000.00 |
17 |
FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN NURNBERG
Organization address
address: SCHLOSSPLATZ 4 contact info |
DE (ERLANGEN) | participant | 15˙416.17 |
18 |
DSM Nutritional Products Ltd
Organization address
address: Wurmisweg 576 contact info |
CH (Kaiseraugst) | participant | 0.00 |
19 |
FERRARI STEPHEN MARIO
Organization address
address: FELDGUETLIWEG 152 contact info |
CH (FELDMEILEN) | participant | 0.00 |
20 |
MAETZEL ANDREAS - MAETZEL CONSULTING
Organization address
address: BAARERSTRASSE 12 contact info |
CH (ZUG) | participant | 0.00 |
21 |
NESTEC S.A
Organization address
address: Avenue Nestle 55 contact info |
CH (VEVEY) | participant | 0.00 |
22 |
NOVAMEN SAS
Organization address
city: LYON contact info |
FR (LYON) | participant | 0.00 |
23 |
ROCHE DIAGNOSTICS (SCHWEIZ) AG
Organization address
address: INDUSTRIESTRASSE 7 contact info |
CH (ROTKREUZ) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'As the European population is ageing rapidly, the growing number of seniors with age-related chronic diseases poses a challenge on European societies and health care systems. Therapeutic interventions that are effective, affordable and well-tolerated in the prevention of chronic disease are urgently needed and will have an outstanding impact on public health as a whole. Among the most promising interventions that meet these requirements are vitamin D, marine omega-3 fatty acids and physical exercise. However, their individual and combined effects have yet to be confirmed in a clinical trial. The DO-HEALTH will close this knowledge gap in a large 3-year multi-centre clinical trial that will establish long-term efficacy and safety data for the 3 interventions in the prevention of age-related diseases in seniors. The DO-HEALTH trial will enrol 2152 community-dwelling men and women aged 70 and older, when chronic diseases increase substantially. The randomized-controlled trial will test the individual and the combined benefit of 2000 IU vitamin D/day, 1 g of omega-3 fatty acids/day and a simple home exercise program in an efficient factorial trial design. DO-HEALTH will establish evidence in 5 primary endpoints: the risk of incident non-vertebral fractures; the risk of functional decline; the risk of blood pressure increase; the risk of cognitive decline; and the rate of any infection. Key secondary endpoints include risk of hip fracture, rate of falls, pain in symptomatic knee osteoarthritis, glucose tolerance, gastro-intestinal symptoms, mental and oral health, quality of life, and mortality. Follow-up will be in-person, in 3-monthly intervals (4 clinical visits and 9 phone calls). DO-HEALTH will further assess the comparative effectiveness of the interventions by evaluating reasons why or why not seniors adhere to them, and will assess their cost-benefit in a health economic model based on documented health care utilization and observed incidence of chronic disease.'
Health Services Research into European Policy and Practice: preparation and organisation of a European Health Services Research Conference
Read MoreOperations management and demand-based approaches to healthcare outcomes and cost-benefits research
Read MoreDevelopment of very promising humanized therapeutic mAbs efficiently neutralizing a novel immunosuppressive pathway involved in a wide range of cancers
Read More